In our ex vivo tests, NPM1-mutated AML cells showed an increased sensitivity to Nut-3a and the drug combination compared with NPM1-wt cases (excluding TP53-mut patients), suggesting a potential vulnerability. The gene discussed is TP53; the disease is acute myeloid leukemia.